Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
17%(1 trials)

Phase Distribution

Ph phase_1
3
50%
Ph phase_2
3
50%

Phase Distribution

3

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
3(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (50.0%)
Phase 23 (50.0%)

Trials by Status

completed6100%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia

NCT01009060
completedphase_1

GSK239512 DDI Study

NCT01802931
completedphase_1

Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease

NCT00675090
completedphase_2

Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease

NCT01009255
completedphase_2

Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis

NCT01772199
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT01009060Phase 2

Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia

Completed
NCT01802931Phase 1

GSK239512 DDI Study

Completed
NCT00675090Phase 1

Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease

Completed
NCT01009255Phase 2

Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease

Completed
NCT01772199Phase 2

Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis

Completed
NCT00474513Phase 1

An Imaging Study to Investigate the Distribution of GSK239512 in the Brain.

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6